Although antibodies have gained plenty of ground in recent years as vehicles for cancer therapies, Aridis Pharmaceuticals wants to use them as nature intended – to fight infection.
“These are human monoclonal antibodies being investigated as anti-infectives to treat bacterial infections associated with pneumonia,” founder & CEO Vu Truong told Drug Delivery Business News, referring to the company’s projects that are in pivotal trials.
“The fundamental reason is that this is exactly what the antibody is designed to do – that is, to fight infection,” he explained.
Get the full story at our sister site, Drug Delivery Business News.
The post Aridis uses human antibodies to fight against “time bomb” of antibiotic resistance appeared first on MassDevice.
from MassDevice http://ift.tt/2hGC3x5
Cap comentari:
Publica un comentari a l'entrada